What happened with EBS today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Emergent BioSolutions earns most of its revenue from products used to prepare for and respond to threats such as smallpox and anthrax. Governments buy vaccines such as ACAM2000, BioThrax and CYFENDUS, along with treatments, for emergency reserves. The U.S. government is its largest customer and buys primarily for the Strategic National Stockpile, generally under long-term, fixed-price contracts with annual purchase options.
Its other major business sells nasal sprays that reverse opioid overdoses. NARCAN supplies most commercial-product revenue and reaches public-health agencies, community organizations and consumers through retail pharmacies and online sellers. NARCAN is available without a prescription in the United States; KLOXXADO requires one. Emergent holds exclusive U.S. and Canadian sales and marketing rights to Hikma Pharmaceuticals’ KLOXXADO.
Emergent also earns fees for developing and manufacturing medicines for outside customers, plus research contracts and grants. These are smaller revenue sources, and it has reduced its emphasis on Bioservices.
The business depends on government funding, purchase-option decisions and delivery timing. Production also relies on single-source suppliers, including every NARCAN component. Manufacturing must meet FDA quality requirements, and products that fail required release testing cannot be sold.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Beyond this list, watch Bavarian Nordic’s Jynneos competing with ACAM2000 for government smallpox and mpox vaccine procurement, and Hikma’s licensed KLOXXADO product—both matter to Emergent’s results.
SIGA Technologies competes with Emergent for government stockpile purchases: its TPOXX and Emergent’s TEMBEXA both treat smallpox. Watch government orders for TPOXX for signs of procurement demand and competition facing TEMBEXA.
Teva threatens Emergent’s NARCAN sales with generic naloxone nasal spray and settlement commitments to supply states overdose-reversal medicines at no cost for 10–15 years. Watch those state supplies: free alternatives can erode the revenue Emergent earns selling NARCAN to government and public-health customers.
Amneal Pharmaceuticals’ generic naloxone nasal spray can take sales from Emergent’s NARCAN and put pressure on its price. Amneal sells generic medicines into retail markets; watch its nasal naloxone business for competition against NARCAN, which Emergent sells through retailers and to public-health buyers.
Amphastar Pharmaceuticals’ Rextovy nasal spray competes with Emergent’s NARCAN and KLOXXADO to reverse opioid overdoses. Watch Rextovy rather than Amphastar’s overall revenue to follow this rivalry with Emergent’s rescue sprays, sold through pharmacies and to government and public-health buyers.
Emergent relies on rights licensed by Indivior Pharmaceuticals to the naloxone formulations in NARCAN, which it sells to public-health customers and through retail channels. Indivior also sells SUBLOCADE and SUBOXONE Film to treat opioid use disorder, so its treatment business addresses the same public-health crisis rather than the same rescue use.
Emergent pays MacroGenics to develop and manufacture bulk drug substance, making it a supplier to watch for outsourced production. MacroGenics recorded $10.7 million of revenue from these manufacturing agreements in 2025; progress on the Emergent work is more relevant here than its antibody-development pipeline.
Emergent Biosolutions, Inc. earningsThis company
Emergent BioSolutions' report will show whether naloxone sales can withstand generic competition and government medical-countermeasure deliveries can support revenue and margins.
Read Commercial Products' naloxone sales alongside MCM Products revenue and gross margin—the sales left after product costs and intangible-asset amortization. If naloxone sales hold against generic competition and MCM deliveries lift revenue without thinning margins, both businesses are supporting Emergent. If naloxone sales keep falling and MCM revenue or margins also weaken, the company is more dependent on uneven government orders and has less profit cushion. Separate swings caused by delivery timing or government purchase options from a lasting change in demand.
Amneal Pharmaceuticals, Inc. earningsAMRX
If Amneal reports nasal naloxone sales or volume, its results will show whether generic competition in pharmacies is gaining ground against Emergent's NARCAN.
If Amneal breaks out nasal naloxone sales or volume, read those figures separately from its overall results. Growth in the product—especially if volume holds up amid price competition—would show stronger generic pressure in pharmacies and could weigh on Emergent's NARCAN retail sales or pricing. Weak product results would offer less evidence that this rival is gaining ground, but would not show that NARCAN sales are improving. Amneal's pharmacy business does not represent Emergent's government and public-health channels.
SIGA Technologies Inc. earningsSIGA
SIGA Technologies' report will show whether government purchases of its smallpox treatment TPOXX are adding competition for Emergent's TEMBEXA.
Read SIGA's TPOXX sales or government-order disclosures alongside the change in its total revenue. If TPOXX sales grow and SIGA attributes that to government purchases, buyers are ordering a competing smallpox treatment, making procurement competition for Emergent's TEMBEXA more relevant. If TPOXX sales weaken, there is less evidence that SIGA is winning purchases, but that does not establish that Emergent received them. Competition does not mean one company's orders automatically transfer to the other.
MacroGenics, Inc. earningsMGNX
MacroGenics' report can show whether its outsourced development and manufacturing work for Emergent is progressing.
Focus on any manufacturing revenue or project update MacroGenics specifically attributes to its work for Emergent, and compare it with the broader trend in its manufacturing-agreement revenue; antibody-pipeline results do not measure this supplier relationship. Rising work-related revenue or an on-track update would support the view that the outsourced work is progressing. Falling revenue or a delay could flag a schedule risk, but MacroGenics' results alone cannot establish that Emergent's production was affected.
